| Ytd | -48.91% | |
| 1y | -64.88% |
| Open | 2.56 | Prev Close | 2.56 | Low | 2.56 | High | 2.85 | Mkt Cap | 6.15M |
| Vol | 76.02K | Avg Vol | 478.65K | EPS | -4.89 | P/E | N/A | Forward P/E | -0.79 |
| Beta | 1.30 | Short Ratio | 0.65 | Inst. Own | 3.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.09 | 200-d Avg | 4.81 | 1yr Est | 7.50 |
LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:AD
About the TransactionsThe acquisition of Azora was structured as an asset acquisition pursuant to wh